HC Wainwright Issues Pessimistic Forecast for Keros Therapeutics (NASDAQ:KROS) Stock Price

Keros Therapeutics (NASDAQ:KROS - Get Free Report) had its price target reduced by stock analysts at HC Wainwright from $100.00 to $47.00 in a research report issued to clients and investors on Friday, Marketbeat Ratings reports. The brokerage presently has a "buy" rating on the stock. HC Wainwright's target price would suggest a potential upside of 153.37% from the company's previous close.

Several other analysts have also issued reports on the stock. Scotiabank assumed coverage on Keros Therapeutics in a research report on Wednesday, October 16th. They issued a "sector outperform" rating and a $77.00 price objective for the company. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. Jefferies Financial Group assumed coverage on shares of Keros Therapeutics in a research report on Tuesday, November 5th. They issued a "buy" rating on the stock. Wells Fargo & Company lifted their target price on shares of Keros Therapeutics from $88.00 to $111.00 and gave the stock an "overweight" rating in a report on Wednesday. Finally, BTIG Research cut shares of Keros Therapeutics from a "buy" rating to a "neutral" rating in a report on Thursday. Three investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, Keros Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $85.67.

Keros Therapeutics Price Performance

Shares of Keros Therapeutics stock traded up $0.12 on Friday, hitting $18.55. The company had a trading volume of 4,680,375 shares, compared to its average volume of 454,214. The stock has a 50-day moving average of $59.95 and a 200-day moving average of $52.83. Keros Therapeutics has a twelve month low of $15.67 and a twelve month high of $73.00. The firm has a market capitalization of $751.40 million, a P/E ratio of -3.45 and a beta of 1.20.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts' consensus estimates of ($1.28) by ($0.13). The firm had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. Keros Therapeutics's quarterly revenue was up 4750.0% on a year-over-year basis. During the same quarter last year, the business posted ($1.33) EPS. Equities analysts predict that Keros Therapeutics will post -5.26 EPS for the current year.

Institutional Trading of Keros Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. KBC Group NV raised its holdings in shares of Keros Therapeutics by 52.0% during the third quarter. KBC Group NV now owns 1,263 shares of the company's stock valued at $73,000 after purchasing an additional 432 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company's stock worth $77,000 after acquiring an additional 280 shares in the last quarter. Values First Advisors Inc. acquired a new stake in Keros Therapeutics in the third quarter valued at approximately $89,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Keros Therapeutics during the second quarter valued at approximately $128,000. Finally, LMR Partners LLP acquired a new position in shares of Keros Therapeutics during the third quarter worth approximately $213,000. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.